Form 4: J&J Executive Sells Common Stock

Timothy Schmid, EVP and WW Chair of MedTech at Johnson & Johnson, reported the sale of 1,322 shares of common stock.

Summary

• Timothy Schmid, Executive Vice President and Worldwide Chairman of MedTech at Johnson & Johnson (JNJ), sold 1,322 shares of JNJ common stock.
• The transaction occurred on February 20, 2026, at a price of $245.66 per share.
• Following the sale, Mr. Schmid directly beneficially owns 25,447 shares of common stock.
• Mr. Schmid also indirectly owns 46 shares through the Johnson & Johnson Savings Plan ESOP and 745 shares through dividend reinvestment in the Johnson & Johnson Stock Fund under the 401k plan, as of January 31, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. Insider sales are common for personal financial planning and do not necessarily indicate a negative outlook for the company, especially given the relatively small number of shares sold compared to JNJ's market capitalization.

Negatives

• An executive selling shares can sometimes be interpreted by the market as a lack of confidence in the company's near-term prospects, although it can also be for personal financial planning.

Risks

• Potential negative market perception if investors interpret the insider sale as a signal of future underperformance.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that insider sales are a routine part of executive compensation and personal financial management. While a single transaction of this size for a company like Johnson & Johnson is unlikely to significantly impact market sentiment, sustained or widespread insider selling across multiple executives could warrant closer scrutiny by investors.

Stakeholder Impact

• Shareholders: May observe the insider sale, but for a company of JNJ's size, this specific transaction is unlikely to have a material impact on shareholder value or confidence.

Key Dates

Recommendation

A single insider sale of this magnitude for a large, diversified company like Johnson & Johnson is typically not a strong signal for a 'buy' or 'sell' recommendation. It's more likely a personal financial decision by the executive. Investors should continue to evaluate JNJ based on its broader financial performance, strategic initiatives, and market conditions rather than this isolated transaction.

Keywords

JNJ, Johnson & Johnson, Timothy Schmid, insider sale, Form 4, executive stock transaction, common stock